TP53 or Not TP53: That Is the Question.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36197410.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2664.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens. See related article by Pollyea et al., p. 5272.
Medical subject headings
- Azacitidine
- Leukemia, Myeloid, Acute